Sign in
Enrolling by invitationNo phase

Long-term safety follow-up for people treated with A2 Bio gene therapy products

Follows adults who received A2 Bio gene therapy for cancers, watching for late safety problems.

Key facts

Who runs it
A2 Biotherapeutics Inc.
Where
Gilbert, New York, and Rochester, United StatesSee the 3 sites
Trial code
Registry title
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
Status
Enrolling by invitation
People taking part
400 people, planned
Started
31 Jul 2025
Expected to end
31 Mar 2040
Type of study
Observational
Treatments tested
  • No additional intervention administered in this long term follow-up study
Record updated
20 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who already received an A2 Bio gene therapy product in an earlier A2 Bio study. It follows them over the long term to watch for delayed safety problems.

Age
18 years or older
Sex
All sexes can join.
Earlier treatment
Must have received any amount of an A2 Bio gene therapy product in a previous A2 Bio interventional study.

Main reasons for not taking part

  • The record lists no specific exclusion criteria.

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Received any amount of A2 Bio GT product on a previous A2 Bio interventional study
  • Able to provide written informed consent for this long-term follow-up study
  • Able to comply with study requirements

Who cannot take part

  • There are no specific exclusion criteria for this study

Where in United States

  • Banner HealthGilbert, United StatesEnrolling by invitation
  • NYU Langone Medical CenterNew York, United StatesEnrolling by invitation
  • Mayo ClinicRochester, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.

The group in the trial

  • Participants that received A2 Bio GT products

    Treatment: No additional intervention administered in this long term follow-up study

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2Bio) Gene Therapy (GT) Products
Plain-language title
Long-term safety follow-up for people treated with A2 Bio gene therapy productsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
20 May 2026